Free Trial
→ Uranium Mine Flood That Sparked a 2006 Price Surge Returns (From Digest Publishing) (Ad)tc pixel
NASDAQ:CLLS

Cellectis Q3 2026 Earnings Date & Estimates

Cellectis logo
$1.11 -0.01 (-0.89%)
Closing price 11/10/2026 04:00 PM Eastern
Extended Trading
$1.25 +0.14 (+12.16%)
As of 06:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cellectis is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for November 13, 2026 at 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cellectis in Q3 2026

Cellectis is expected to post earnings of -$0.18 per share on revenue of $15.61 million. In the same quarter a year earlier Cellectis reported $0.01 per share on revenue of $37.16 million. Cellectis last reported on August 7, 2026, posting -$0.22 per share and beating the -$0.2630 consensus estimate. Cellectis has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.18
Expected Revenue
$15.61 million
Prior-Year EPS
$0.01
Prior-Year Revenue
$37.16 million
Expected EPS Growth
-1,900.0%
Expected Revenue Growth
-58.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.22 (Beat by +$0.0430)
Last Quarter Revenue
$6.90 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Cellectis Q3 2026 Earnings FAQ

Cellectis (NASDAQ:CLLS) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Cellectis' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cellectis to post earnings of -$0.18 per share for Q3 2026.

The consensus revenue estimate for Cellectis is $15.61 million for Q3 2026.

Cellectis Earnings Headlines

Cellectis to Report Third Quarter Financial Results on November 12, 2026
November 9 at 4:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/09/3399025/0/en/cellectis-to-report-third-quarter-financial-results-on-november-12-2026.html
Head to Head Analysis: Amylyx Pharmaceuticals (NASDAQ:AMLX) and Cellectis (NASDAQ:CLLS)
November 8 at 3:59 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31186143
Your Copy is Available to Claim
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
November 11 at 1:00 AM  |  Paradigm Press (Ad)
Cellectis (CLLS) Projected to Announce Earnings on Friday
November 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31180910
Cellectis S.A. (CLLS)
November 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/CLLS/latest-news/
Cellectis' .HEAL-101 Lowers Triglycerides In Preclinical Study; Phase 1 Data Expected In H2'27
October 28, 2026  |  rttnews.comhttps://www.rttnews.com/3704216/cellectis-heal-101-lowers-triglycerides-in-preclinical-study-phase-1-data-expected-in-h2-27.aspx
See More Cellectis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email.

About Cellectis

Cellectis (NASDAQ:CLLS) is a biotechnology company focused on developing gene-edited cell therapies for the treatment of cancer and other serious diseases. Founded in France in 1999, the company pioneered the use of TALEN gene-editing technology to modify immune cells and develop off-the-shelf, or allogeneic, treatments.

The company’s primary programs involve genetically modified T cells, including its UCART platform of allogeneic chimeric antigen receptor T-cell therapies. These products are designed to target specific cancer antigens and are being investigated in clinical studies for hematologic malignancies and other cancers. Cellectis also develops gene-editing technologies intended to improve the persistence, safety and effectiveness of engineered immune cells.

Cellectis operates internationally, with activities in Europe and the United States, and has collaborated with pharmaceutical and biotechnology companies to advance its cell therapy programs. Its shares trade on Nasdaq under the symbol CLLS, while the company’s ordinary shares are also listed in France.

View Cellectis Profile
Earnings Tools